ConvaTec consensus holds steady, analysts eye defensive healthcare stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 14:05.

ConvaTec Group Plc (GB00BD3VFW73) sits in the healthcare segment of the London Stock Exchange with a market capitalization around 4.2 billion pounds, based on recent data from Hargreaves Lansdown and MarketBeat.Hargreaves Lansdown price overview The shares trade under the ticker CTEC in London, giving international investors exposure to a defensive medical technology name alongside peers such as Smith & Nephew.

What recent data shows

According to MarketBeat, ConvaTec shares most recently changed hands at just over 210 pence, leaving the stock on a price-to-earnings ratio close to 16 and a dividend yield of roughly 2.5 percent in sterling terms.MarketBeat snapshot for ConvaTec Hargreaves Lansdown cites a market cap of approximately 4.18 billion pounds, underlining the mid-cap profile of the company within the UK healthcare universe.Hargreaves Lansdown valuation metrics

The latest dividend data point shows a cash distribution of 0.04 pounds per share, with an ex-dividend date recorded as 16 April 2026 and a payment date on 28 May 2026, confirming the regular income stream profile.Dividend timetable and yield details Daily volume reported around 7.8 million shares indicates solid liquidity for retail and institutional participants using the London venue.

Analyst and consensus picture

MarketBeat aggregates analyst ratings for ConvaTec, reporting a mixed but broadly constructive stance, with several houses maintaining Buy or Outperform calls and others on Hold, resulting in a consensus leaning toward moderate upside expectations.MarketBeat analyst consensus page The compiled price targets cluster above the current share price region, indicating that analysts still see room for incremental value over the medium term, albeit with the typical healthcare-sector caution.

ConvaTec’s valuation at a mid-teens earnings multiple and a yield just over 2.5 percent puts it between pure growth medtech names and higher-yielding large-cap pharma, a positioning that analysts highlight when comparing the stock to peer-group companies in wound care and continence management.Peer comparison and rating distribution For UK retail investors, the combination of liquidity, established dividend practice and stable coverage by London-based brokers supports continued interest in the CTEC shares.

How ConvaTec makes its money

ConvaTec generates revenue through medical products in advanced wound care, ostomy care, continence and critical care, and infusion devices, serving hospitals, homecare providers and individual patients worldwide.Company business overview Flagship lines include AQUACEL wound dressings and me+ ostomy support services, which anchor recurring demand in chronic care markets and underpin the company’s cash flow profile.

Where the shares trade today

The ConvaTec Group Plc shares (GB00BD3VFW73) most recently traded on the London Stock Exchange at around 213 pence in sterling, with the latest available quote reflecting data as of 2026-06-29, 12:05 UK time.Latest London trading quote for CTEC

Disclaimer: This text is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. All data are based on sources deemed reliable but may be subject to change. Investors should conduct their own research and, where appropriate, seek professional advice.